Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Macitentan Dispersible FMI vs Opsumit in Healthy Adults
NCT05433675Phase 1Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jun 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of macitentan in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Maximum Observed Plasma Analyte Concentration of Macitentan at Day 10, Area Under the Plasma Analyte Concentration Versus Time Curve From Time Zero To Time of the Last Quantifiable Concentration of Macitentan at Day 10 and 1 more. Started Jun 2022; status: completed.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05433675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05433675.